Read More

Impel Pharmaceuticals Earlier Announced Streamlining Plan, Including 16% Workforce Reduction, Largely In The R&D Functions, The Company Plans To Reprioritize Spending On Trudhesa (Dihydroergotamine Mesylate) Nasal Spray For Migraine

The plan will halt research and development efforts on INP105 (olanzapine) to address acute agitation and aggression in autism spectrum disorder.  Aligned with this, the Company also announced that Stephen

IMPL

Read More

GSK, Pfizer And Shionogi Owned ViiV Healthcare Announced 12-month Findings From The Solar Phase 3B Head-to-head Study Of Long Acting Cabenuva Regime (CAB+RPV LA) Compared Against Gilead’s Biktarvy Regime (BIC/FTC/TAF)

Study findings showed that CAB+RPV LA dosed every two months achieved the primary endpoint of non-inferior virologic efficacy versus daily oral BIC/FTC/TAF, while 90% of participants who switched to CAB+RPV

GSK